Aragon Pharmaceuticals
About Aragon Pharmaceuticals
Company overview
Aragon Pharmaceuticals is a biotechnology company focused on discovering and developing small-molecule therapeutics for hormonally-driven cancers, with an emphasis on overcoming resistance to existing endocrine therapies. Their product strategy is built around novel androgen receptor (AR) antagonists and selective estrogen receptor degraders (SERDs) that aim to treat prostate, breast and other hormone-dependent cancers. Product / Technology Breakdown Androgen receptor antagonist portfolio: Their lead candidate, ARN-509 (now known as apalutamide), is a second-generation AR signaling inhibitor developed for castration-resistant prostate cancer (CRPC). This compound blocks AR nuclear translocation and DNA binding, thereby inhibiting AR-driven tumour growth. Selective estrogen receptor degrader (SERD) platform: In parallel, Aragon developed compounds designed to degrade the estrogen receptor rather than simply antagonise it. This SERD platform targets hormone-sensitive and hormone-resistant breast cancer. Discovery and translational research engine: The company's platform is founded on nuclear-receptor biology, medicinal chemistry and small-molecule drug discovery methods. They aim to develop compounds that are mechanistically distinct from first-generation endocrine therapies and better able to circumvent resistance. Pipeline progression & strategic exit: Although Aragon did not itself launch large-scale commercial products, its strategic value lies in advancing early to mid-stage candidates and then partnering or being acquired by a larger pharma company to take them through late-stage development and commercialization. For example, their acquisition by Johnson & Johnson (via its oncology arm) included the AR antagonist program ARN-509.
Keywords
Revenue
EBITDA
Valuation
| Line Item | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenues | $380 MM | $250 MM | $90 MM | $120 MM | $65 MM |
| Gross Profit | $190 MM | $125 MM | $45 MM | $60 MM | $32.50 MM |
| Net Income (Loss) | $43 MM | $25 MM | $9 MM | $12 MM | $6.50 MM |
| Line Item | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Assets | $850 MM | $720 MM | $680 MM | $650 MM | $600 MM |
| Total Liabilities | $450 MM | $400 MM | $380 MM | $350 MM | $320 MM |
| Total Equity | $400 MM | $320 MM | $300 MM | $300 MM | $280 MM |
Ratios
Employee Figures
Key Executives
| Name | Title | Socials | Phone | |
|---|---|---|---|---|
| John Doe | Employee | ---------- | ---------- | ---------- |
| Jane Doe | Employee | ---------- | ---------- | ---------- |
| John Doe | Employee | ---------- | ---------- | ---------- |
| John Doe | Employee | ---------- | ---------- | ---------- |
401K
M&A2024-03-15Completed
Investor Sponsors NorthBridge PE | Stake Tags 100% |
Deal Amount $120M | Is PE deal Yes |
Target Company Valuation $1.20 MM | Is deal PE backed Yes |
Techniques Acquisition of Assets, Taken Private | Total Acquired 100% |
Investor Sponsors
Deal Amount
$120M
Target Company Valuation
$1.20 MM
Techniques
Acquisition of Assets, Taken Private
Stake Tags
100%
Is PE deal
Yes
Is deal PE backed
Yes
Total Acquired
100%
Secondary Transaction2023-09-01Canceled
Investor Sponsors -- | Stake Tags Majority |
Deal Amount Undisclosed | Is PE deal No |
Target Company Valuation -- | Is deal PE backed Yes |
Techniques Secondary Sale, Management Buy-out (MBO) | Total Acquired 65% |
Investor Sponsors
--
Deal Amount
Undisclosed
Target Company Valuation
NaN
Techniques
Secondary Sale, Management Buy-out (MBO)
Stake Tags
Majority
Is PE deal
No
Is deal PE backed
Yes
Total Acquired
65%
© 2026 PrivCo Holding Inc. All rights reserved.
No AI Training or Automated Data Extraction.
Use of this page or any content or data made available by PrivCo for scraping, crawling, indexing, caching, extracting, copying, reproducing, storing, or for training or developing any artificial intelligence or machine learning system is strictly prohibited without prior written consent. All access to and use of this page and PrivCo's services are subject to the PrivCo Terms of Use: https://www.privco.com/terms-of-use. No license or right is granted by implication or otherwise.